What BDNF Actually Does. Part Three: What a Blood Test Cannot Tell You

Abstract

The previous two parts described BDNF inside the brain: a protein processed into forms with opposing actions, and a common variant that alters that processing. This part deals with the only version of BDNF anyone is likely to encounter in practice — a number from a blood sample.

Two large meta-analyses anchor the discussion. Dinoff and colleagues pooled twenty-nine studies on whether exercise training raises resting peripheral BDNF. Fernandes and colleagues pooled fifty-two studies comprising 6,481 people on whether peripheral BDNF works as a biomarker in bipolar disorder.

The results are more useful than the individual studies that circulate. One of them, in particular, is a number worth memorising before reading any claim that some intervention raises BDNF.

1.The Assumption Everything Rests On

The entire enterprise of measuring BDNF in blood depends on a premise that is usually stated in a single clause and then not revisited: that peripheral levels reflect what is happening in the brain.

The Fernandes review states the rationale directly — BDNF levels in peripheral blood can be assessed easily and relatively non-invasively, and serum and plasma levels are held to correlate with central nervous system levels on the grounds that BDNF crosses the blood-brain barrier.

We flag it here not to declare it false, but because it is load-bearing and rarely examined by anyone citing a BDNF result. Everything downstream — every claim that an activity raised someone's BDNF and therefore did something to their brain — inherits whatever uncertainty attaches to that premise.

There is also a complication in the sample itself. BDNF is stored in platelets, which are activated during clotting and release their contents into serum, so serum concentrations are substantially higher than plasma concentrations. Plasma BDNF represents the freely circulating fraction and, as the exercise meta-analysis notes, may have a different physiological role. Two laboratories can measure 'BDNF' in the same person and obtain numbers that are not comparable.

2.Does Exercise Raise It? The Number to Remember

Exercise is the intervention most consistently linked to BDNF in popular writing, and the claim has a real basis: acute exercise does appear to produce a reasonably consistent short-term rise in peripheral BDNF.

The more interesting question is whether training changes the resting level — whether becoming a person who exercises leaves you with more BDNF in general. Dinoff and colleagues examined exactly this across twenty-nine studies.

The qualitative breakdown is the part we would put on a poster. Nine of the twenty-nine studies, or 31.0 per cent, reported a significant increase in resting peripheral BDNF. No study reported a significant decrease. And twenty studies, 69.0 per cent, reported no significant change at all.

Roughly two in three studies found nothing. Heterogeneity across the pooled studies was considerable — an I² of 75 per cent — meaning the studies disagreed with one another well beyond what sampling variation would explain. Subgroup analyses found no significant difference between studies of men and women, and none between serum and plasma measurement, though the latter comparison was limited by how few studies used plasma.

The authors situate this against earlier work, noting a previous conclusion that chronic exercise training was unlikely to increase resting BDNF concentrations, and another meta-analysis reporting a small but significant increase. The honest summary is that the acute effect is reasonably solid and the durable resting effect is small at best and inconsistently detected.

3.What a Biomarker Would Have to Do

The bipolar disorder literature is instructive because it represents the most serious attempt to make peripheral BDNF do real clinical work, backed by fifty-two studies and 6,481 participants.

The finding is genuinely interesting. Peripheral BDNF levels were equally decreased during manic and depressive episodes, and appeared normal in euthymia — the periods between episodes. That is the signature of a state marker: something that tracks the current condition rather than identifying who has the illness.

One further detail deserves attention from anyone hoping BDNF indexes cognitive capacity. The review notes there is no correlation between cognition and peripheral BDNF levels in euthymia. Where it has been looked for directly, in a well-studied population, the link between the blood number and how well someone thinks was not there.

4.What This Means for Anything Sold on Raising BDNF

Assembling the three parts of this series produces a fairly clear position, and it is more restrictive than the popular account by some distance.

The protein exists in forms that push synapses in opposite directions, so a single total quantity does not specify which is happening. The measurement available in practice is taken from blood rather than brain, and depends on a premise that is assumed more often than tested. The sample type materially changes the number. Roughly two-thirds of training studies find no change in resting levels. And where the relationship with cognition has been tested directly in a stable population, it was absent.

Against that, a claim that a product raises BDNF is doing several things at once: assuming the blood number reflects the brain, assuming more is better despite the opposing arms, and assuming an effect that most exercise studies could not detect for an intervention with far stronger physiological credentials.

None of this makes BDNF unimportant. It is central to synaptic plasticity and the mechanistic literature is substantial. It makes BDNF a poor consumer metric — genuinely important and, as currently measurable, close to useless as a personal readout.

5.What Would Change Our Reading

We try to state this for any topic where we land on a negative, because a position that nothing could revise is not a scientific position.

Direct evidence on how well peripheral BDNF tracks central BDNF within the same individuals would settle the largest uncertainty. Standardisation of sample type and assay would remove a substantial source of the heterogeneity seen across studies. And measurement able to distinguish the mature protein from the precursor and pro-peptide would address the deepest problem, since a total that sums molecules with opposing actions is difficult to interpret whatever its value.

Until then, the reasonable stance is that BDNF is a molecule worth understanding and a number not worth chasing.

Editorial Comment

MindHeaven® makes no claim that any product raises BDNF, and after reading this literature we would not make one even if a study reported it. The measurement problems described above mean that a rise in a blood value would not establish a benefit, and the opposing actions of the mature and precursor forms mean that more is not straightforwardly better.

This series has no formulation note attached to it, unlike some others in this library. That is not an oversight. None of our compounds has been shown to affect this system, and the honest thing to do with a topic where we have nothing to contribute is to write it well and leave the product out of it.